Application of toxicogenomic tools in the drug research and development process

Toxicology Letters

Volumn 186, Issue 1, 2009, Pages 13-17

  Fabre, Nicolas ^a   Anglade, Isolde ^a   Vericat, Joan Albert ^a  

^a Drug Discovery   (Spain)

Author keywords

Drug development; Gene expression; In vitro; In vivo; Toxicity; Toxicogenomics

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; COST BENEFIT ANALYSIS; DECISION MAKING; DRUG RESEARCH; DRUG SAFETY; EXPERIMENTAL MONKEY; GENE EXPRESSION; GOOD LABORATORY PRACTICE; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; TOXICOGENETICS;

ANIMALS; BIOMEDICAL RESEARCH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMANS; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; TOXICITY TESTS; TOXICOGENETICS;

ANIMALIA;

EID: 61349155450     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2009.01.012     Document Type: Article

References (34)

1. Abraham V.C., Towne D.L., Waring J.F., Warrior U., and Burns D.J. Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans. J. Biomol. Screen. 13 6 (2008) 527-537
2. Buck W.R., Waring J.F., and Blomme E.A. Use of traditional end points and gene dysregulation to understand mechanisms of toxicity: toxicogenomics in mechanistic toxicology. Methods Mol Biol. 460 (2008) 23-44
3. Chin K.V., and Kong A.N. Application of DNA microarrays in pharmacogenomics and toxicogenomics. Pharm. Res. 19 12 (2002) 1773-1778
4. Combes R.D., Gaunt I., and Balls M. A scientific and animal welfare assessment of the OECD Health Effects Test Guidelines for the safety testing of chemicals under the European Union REACH system. Altern. Lab. Anim. 32 3 (2004) 163-208
5. Cullen J.M., and Miller R.T. The role of pathology in the identification of drug-induced hepatic toxicity. Expert Opin. Drug Metab. Toxicol. 2 2 (2006) 241-247
6. Decristofaro M.F., and Daniels K.K. Toxicogenomics in biomarker discovery. Methods Mol. Biol. 460 (2008) 185-194
7. FDA challenge and opportunity on the critical path to new medical products, March 2004.
8. FDA draft guidance for industry: pharmacogenomic data submissions, August 2007.
9. Fenwick N.P., and Fraser D. The three Rs in the pharmaceutical industry: perspectives of scientists and regulators. Anim. Welf. 14 (2005) 367-377
10. Foley J.F., Collins J.B., Umbach D.M., Grissom S., Boorman G.A., and Heinloth A.N. Optimal sampling of rat liver tissue for toxicogenomic studies. Toxicol. Pathol. 34 6 (2006) 795-801
11. Foster W.R., Chen S.J., He A., Truong A., Bhaskaran V., Nelson D.M., Dambach D.M., and Car B.D. A retrospective analysis of toxicogenomics in the safety assessment of drug candidates. Toxicol. Pathol. 35 (2007) 621-635
12. Freeman K. Toxicogenomics data; a roadmap to acceptance. Environ. Health Perspect. 112 (2004) 678-685
13. Gant T.W. Novel and future applications of microarrays in toxicological research. Expert. Opin. Drug Metab. Toxicol. 3 4 (2007) 599-608
14. Ganter B., Zidek N., Hewitt P.R., Müller D., and Vladimirova A. Pathway analysis tools and toxicogenomics reference databases for risk assessment. Pharmacogenomics 9 1 (2008 Jan) 35-54
15. Han L., Wang Y., and Bryant S.H. Developing and validating predictive decision tree models from mining chemical structural fingerprints and high-throughput screening data in PubChem. BMC Bioinform. Sep. 25 (2008) 9-401
16. Huang, da W., Sherman B.T., Tan Q., Kir J., Liu D., Bryant D., Guo Y., Stephens R., Baseler M.W., Lane H.C., and Lempicki R.A. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 35 (2007) 169-175
17. The Innovative Medicines Initiative (IMI): research agenda; creating biomedical R&D leadership for Europe to benefit patients and society, march 2008.
18. Jacobs A. An FDA perspective on the nonclinical use of the X-Omics technologies and the safety of new drugs. Toxicol. Lett. Sep. (2008) p2
19. Kiyosawa N., Shiwaku K., Hirode M., Omura K., Uehara T., Shimizu T., Mizukawa Y., Miyagishima T., Ono A., Nagao T., and Urushidani T. Utilization of a one-dimensional score for surveying chemical-induced changes in expression levels of multiple biomarker gene sets using a large-scale toxicogenomics database. J. Toxicol. Sci. 31 5 (2006) 433-448
20. Kola I., and Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 3 (2004) 711-715
21. Kramer J.A., Sagartz J.E., and Morris D.L. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat. Rev. Drug Discov. 6 (2007) 636-649
22. Leighton J.K., Brown P., Ellis A., Harlow P., Harrouk W., Pine P.S., Robison T., and Thompson K. Workgroup report: review of genomics data based on experience with mock submissions-View of the CDER pharmacology toxicology nonclinical pharmacogenomics subcommittee. Environ. Health Perspect. 114 4 (2006) 573-578
23. Lord P.G., Nie A., and McMillian M. Application of genomics in preclinical drug safety evaluation. Basic Clin. Pharmacol. Toxicol. 98 6 (2006) 537-546
24. Nieto-Díaz M., Pita-Thomas W., and Nieto-Sampedro M. Cross-species analysis of gene expression in non-model mammals: reproducibility of hybridization on high density oligonucleotide microarrays. BMC Genomics 8 (2007) art. no. 89
25. NTP A NATIONAL TOXICOLOGY PROGRAM for the 21st Century, roadmap to achieve the NTP vision, 2004.
26. Peters T.S. Do preclinical testing strategies help predict human hepatotoxic potentials? Toxicol. Pathology 33 (2005) 146-154
27. Pognan F. Toxicogenomics applied to predictive and exploratory toxicology for the safety assessment of new chemical entities: a long road with deep potholes. Prog. Drug Res. 64 (2007) 217-238
28. Rietjens I.M., and Alink G.M. Future of toxicology-low-dose toxicology and risk-benefit analysis. Chem. Res. Toxicol. 19 (2006 Aug) 977-981
29. Stevens J.L. Future of toxicology-mechanisms of toxicity and drug safety: where do we go from here?. Chem. Res. Toxicol. 19 (2006) 1393-1401
30. Tamura K., Ono A., Miyagishima T., Nagao T., and Urushidani T. Profiling of gene expression in rat liver and rat primary cultured hepatocytes treated with peroxisome proliferators. J. Toxicol. Sci. 31 5 (2006) 471-490
31. Tarr P.E., Telenti A., Waters M., Stasiewicz S., Merrick B.A., Tomer K., Bushel P., Paules R., Stegman N., Nehls G., Yost K.J., Johnson C.H., Gustafson S.F., Xirasagar S., Xiao N., Huang C.C., Boyer P., Chan D.D., Pan Q., Gong H., Taylor J., Choi D., Rashid A., Ahmed A., Howle R., Selkirk J., Tennant R., and Fostel J. CEBS-Chemical Effects in Biological Systems: a public data repository integrating study design and toxicity data with microarray and proteomics data. Nucleic Acids Res. 36 (2008) 892-900
32. Thompson K.L., and Hackett J. Quality control of microarray assays for toxicogenomic and in vitro diagnostic applications. Methods Mol. Biol. 460 (2008) 45-68
33. Uehara T., Kiyosawa N., Shimizu T., Omura K., Hirode M., Imazawa T., Mizukawa Y., Ono A., Miyagishima T., Nagao T., and Urushidani T. Species-specific differences in coumarin-induced hepatotoxicity as an example toxicogenomics-based approach to assessing risk of toxicity to humans. Hum. Exp. Toxicol. 27 1 (2008 Jan) 23-35
34. Wetmore B.A., and Merrick B.A. Toxicoproteomics: proteomics applied to toxicology and pathology. Toxicol. Pathol. 32 (2004) 619-642